Arecor has a proprietary and patented technology platform for improving the stability of a range of therapeutic proteins including vaccines, monoclonal antibodies, peptides, blood factors and fusion proteins
Dr Sarah HowellChief Operations Officer
BioPartner.co.uk & Communications Strategy Group
The Communications Strategy Group Inc. is US-based consultancy providing corporate/financial communications and business development services to the life sciences, biotech and medical technology sectors; assist and advise UK and EU companies seeking to expand to the US; corporate mentoring; assets partnering; capital formation.
The Communications Strategy Group Inc. acts as a contact point for UK companies attending US conferences, in partnership with Biopartner.co.uk, a UK Accredited Trade Organisation facilitating international partnering for trade, investment and collaborations with Life Sciences organisations across the UK. BioPartner is a membership organisation, supporting UK SMEs and startups, and signposting organisations worldwide to UK expertise.
Biopartner.co.uk has alliances with organisers of international biopartnering events, and with UK membership organisations, operating both independently and in partnership with the UK government. BioPartner disseminates tradeshow access grants to help UK-based SMEs exhibit their services and products in new overseas markets.
Mr Ted AgnePresident
Ms Lin Bateson(not attending)
Domainex is a drug discovery company with a reputation for speed and innovation built on an exceptional track record of drug candidate delivery. It has a world class discovery team with an unrivalled track record and three client drug candidates
Dr Eddy LittlerChief Executive Officer
Dr Keith PowellChairman
Haemostatix has developed a new class of peptide-based haemostat for the treatment of bleeding. The technology is based on a peptide that binds to the blood protein fibrinogen, inducing the rapid and targeted formation of clots.
Dr Ben NicholsChief Executive Officer
Integrated Magnetic Systems Ltd
IMS offers magnetic antibodies and adaptor proteins to the life science community (research and bioprocessing) while further developing the technology platform for licensing and partnering opportunities in medicine (diagnostics and therapeutics).
Dr Eddie BlairChief Executive Officer
International Bioscience Managers
IBML, through its associate companies, OctaPhillip Bioscience Managers Ltd and Union MedTech PLC, specialises in investment in life science and medical technology companies.
Mr Jeremy Curnock CookManaging Director
Kymab is a biopharmaceutical company engaged in the discovery and development of human monoclonal antibody therapeutics.
Dr Tom ShepherdChief Business Officer
PolyTherics is a biotechnology company that offers a comprehensive range of site-specific conjugation technologies and polymer-based technologies which are being applied to the development and enhancement of biologicals and other therapeutic entities.
Dr John BurtChief Executive Officer
Dr Jennifer FilbeyUS consultant
Prosonix is a speciality pharmaceutical company developing a portfolio of inhaled respiratory medicines enabled by its state-of-the-art particle engineering technology.